US FDA staff say COVID-19 vaccines being developed and manufactured for the 2023-2024 campaign should target one of the currently dominant XBB variants. According to data collected by the Centers for Disease
Today: February 1, 2026
US FDA staff say COVID-19 vaccines being developed and manufactured for the 2023-2024 campaign should target one of the currently dominant XBB variants. According to data collected by the Centers for Disease